4D Molecular Therapeutics Inc (NASDAQ:FDMT) shares, rose in value on Thursday, April 16, with the stock price up by 5.15% to the previous day’s close as strong demand from buyers drove the stock to $3.06.
Actively observing the price movement in the last trading, the stock closed the session at $2.91, falling within a range of $2.89 and $3.07. The value of beta (5-year monthly) was 2.876. Referring to stock’s 52-week performance, its high was $28.93, and the low was $2.23. On the whole, FDMT has fluctuated by -19.26% over the past month.
With the market capitalization of 4D Molecular Therapeutics Inc currently standing at about $141.69 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-27.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 529.67k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that FDMT’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of FDMT currently trading nearly -2.06% and -22.51% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 44.58, while the 7-day volatility ratio is showing 8.49% which for the 30-day chart, stands at 9.91%. Furthermore, 4D Molecular Therapeutics Inc (FDMT)’s beta value is 2.81, and its average true range (ATR) is 0.31.
A comparison of 4D Molecular Therapeutics Inc (FDMT) with its peers suggests the former has fared considerably weaker in the market. FDMT showed an intraday change of 5.15% in last session, and over the past year, it shrunk by -88.56%%.
Data on historical trading for 4D Molecular Therapeutics Inc (NASDAQ:FDMT) indicates that the trading volumes over the past 10 days have averaged 0.87 and over the past 3 months, they’ve averaged 841.94K. According to company’s latest data on outstanding shares, there are 45.79 million shares outstanding.
Nearly 14.40% of 4D Molecular Therapeutics Inc’s shares belong to company insiders and institutional investors own 91.97% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 5.06 million shares as on 2025-03-31, resulting in a short ratio of 6.76. According to the data, the short interest in 4D Molecular Therapeutics Inc (FDMT) stood at 1137.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 5.24 million. The stock has fallen by -45.06% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the FDMT stock heading into the next quarter.
